Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;78(4):243-57.
doi: 10.3949/ccjm.78a.10145.

Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others

Joseph P Kitzmiller  1 , David K Groen, Mitch A Phelps, Wolfgang Sadee
Affiliations
Review

Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others

Joseph P Kitzmiller et al. Cleve Clin J Med. 2011 Apr.

Abstract

Genetics may account for much of the variability in our patients' responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. It also discusses the future role of pharmacogenomic testing in medicine.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
How a genetic test becomes a standard of care: Typical advancement pathway
FIGURE 2
FIGURE 2
Why some drugs don’t work in some patients
See this image and copyright information in PMC

Comment in

References

    1. King HC, Sinha AA. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA. 2001;286:2280–2288. - PubMed
    1. Nuckols TK, Paddock SM, Bower AG, et al. Costs of intravenous adverse drug events in academic and nonacademic intensive care units. Med Care. 2008;46:17–24. - PubMed
    1. Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse events in two long-term care facilities. Am J Med. 2005;118:251–258. - PubMed
    1. Vargas E, Terleira A, Hernando F, et al. Effects of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003;31:694–698. - PubMed
    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205. - PubMed

MeSH terms